Trial Profile
Phase II study of erlotinib and modified FOLFOX-6 (5-fluorouracil, leucovorin [folinic acid] and oxaliplatin) in previously untreated patients with unresectable or metastatic adenocarcinoma of the esophagus and gastric cardia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Therapeutic Use
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Feb 2008 New trial record.